Cargando…
RCC Immune Microenvironment Subsequent to Targeted Therapy: A Friend or a Foe?
Renal cell carcinoma (RCC) is composed of different subtypes with distinct molecular and histological tumor heterogeneity. Although the advent of various targeted therapies has improved the survival of patients with advanced RCC over the past 15 years (since 2006), few cases experienced complete res...
Autores principales: | Chen, Wenjin, Pan, Xiuwu, Cui, Xingang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561377/ https://www.ncbi.nlm.nih.gov/pubmed/33117708 http://dx.doi.org/10.3389/fonc.2020.573690 |
Ejemplares similares
-
Immune System, Friend or Foe of Oncolytic Virotherapy?
por: Filley, Anna C., et al.
Publicado: (2017) -
The Immune Microenvironment in Multiple Myeloma: Friend or Foe?
por: Lopes, Raquel, et al.
Publicado: (2021) -
Anesthesia and Oncology: Friend or Foe?
por: Buddeberg, Bigna S., et al.
Publicado: (2022) -
Malignancy and IFITM3: Friend or Foe?
por: Rajapaksa, Ushani S., et al.
Publicado: (2020) -
Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?
por: van Schaik, Thijs A., et al.
Publicado: (2021)